Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Postexercise muscle glycogen synthesis with glucose, galactose, and combined galactose-glucose ingestion.
Podlogar T, Shad BJ, Seabright AP, Odell OJ, Lord SO, Civil R, Salgueiro RB, Shepherd EL, Lalor PF, Elhassan YS, Lai YC, Rowlands DS, Wallis GA. Podlogar T, et al. Among authors: civil r. Am J Physiol Endocrinol Metab. 2023 Dec 1;325(6):E672-E681. doi: 10.1152/ajpendo.00127.2022. Epub 2023 Oct 18. Am J Physiol Endocrinol Metab. 2023. PMID: 37850935 Free PMC article. Clinical Trial.
Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
Dittmann RW, Cardo E, Nagy P, Anderson CS, Adeyi B, Caballero B, Hodgkins P, Civil R, Coghill DR. Dittmann RW, et al. Among authors: civil r. CNS Drugs. 2014 Nov;28(11):1059-69. doi: 10.1007/s40263-014-0188-9. CNS Drugs. 2014. PMID: 25038977 Free PMC article. Clinical Trial.
Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design.
Coghill DR, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson CS, Civil R, Dauphin M, Higgins N, Lyne A, Gasior M, Squires LA. Coghill DR, et al. Among authors: civil r. J Am Acad Child Adolesc Psychiatry. 2014 Jun;53(6):647-657.e1. doi: 10.1016/j.jaac.2014.01.017. Epub 2014 Mar 4. J Am Acad Child Adolesc Psychiatry. 2014. PMID: 24839883 Free article. Clinical Trial.
Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, Higgins N, Hodgkins P, Lyne A, Civil R, Coghill D. Dittmann RW, et al. Among authors: civil r. CNS Drugs. 2013 Dec;27(12):1081-92. doi: 10.1007/s40263-013-0104-8. CNS Drugs. 2013. PMID: 23959815 Free PMC article. Clinical Trial.
A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
Soutullo C, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Bloomfield R, Squires LA, Coghill DR. Soutullo C, et al. Among authors: civil r. CNS Drugs. 2013 Sep;27(9):743-51. doi: 10.1007/s40263-013-0086-6. CNS Drugs. 2013. PMID: 23801529 Free PMC article. Clinical Trial.
25 results